Gout, hyperuricemia, and the risk of cardiovascular disease: Cause and effect?

Current Rheumatology Reports

Volumn 12, Issue 2, 2010, Pages 118-124

  Shah, Ankoor ^a   Keenan, Robert T ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; Gout; Hyperuricemia; Inflammation

Indexed keywords

ALLOPURINOL; C REACTIVE PROTEIN; COLCHICINE; DIURETIC AGENT; ENDOTHELIN 1; INTERLEUKIN 6; LOSARTAN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROBENECID; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; URIC ACID; XANTHINE OXIDASE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; FAMILIAL HYPERCHOLESTEROLEMIA; GOUT; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; HYPERURICEMIA; INFLAMMATION; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PRIMARY PREVENTION; PROGNOSIS; REPERFUSION INJURY; REVIEW;

ANIMALS; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; CELLS, CULTURED; CLINICAL TRIALS AS TOPIC; COMORBIDITY; DISEASE MODELS, ANIMAL; GOUT; HUMANS; HYPERURICEMIA; INFLAMMATION MEDIATORS; METABOLIC SYNDROME X; RISK FACTORS; URIC ACID;

EID: 77953480064     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-010-0084-3     Document Type: Review

References (54)

1. Watanabe S, Kang DH, Feng L, et al.: Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002, 40:355-360.
2. So A: Developments in the scientific and clinical understanding of gout. Arthritis Res Ther 2008, 10:221.
3. Hahn BH, McMahon M: Atherosclerosis and systemic lupus erythematosus: the role of altered lipids and of autoantibodies. Lupus 2008, 17:368-370.
4. Hahn BH, Grossman J, Chen W, McMahon M: The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 2007, 28:69-75. This is a good review on how autoimmune rheumatic diseases play a role in accelerated or premature atherosclerosis.
5. Scott P, Ma H, Viriyakosol S, et al.: Engagement of CD14 mediates the inflammatory potential of monosodium urate crystals. J Immunol 2006, 177:6370-6378.
6. di Giovine FS, Malawista SE, Thornton E, Duff GW: Urate crystals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial cells. Cytokine mRNA and protein kinetics, and cellular distribution. J Clin Invest 1991, 87:1375-1381.
7. Kanellis J, Watanabe S, Li JH, et al.: Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003, 41:1287-1293.
8. Rao GN, Corson MA, Berk BC: Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 1991, 266:8604-8608.
9. Corry DB, Eslami P, Yamamoto K, et al.: Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008, 26:269-275.
10. Sharma R, Coats AJ, Anker SD: The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1. Int J Cardiol 2000, 72:175-186.
11. Chao HH, Liu JC, Lin JW, et al.: Uric acid stimulates endothelin-1 gene expression associated with NADPH oxidase in human aortic smooth muscle cells. Acta Pharmacol Sin 2008, 29:1301-1312.
12. Cheng TH, Lin JW, Chao HH, et al.: Uric acid activates extracellular signal-regulated kinases and thereafter endothelin-1 expression in rat cardiac fibroblasts. Int J Cardiol 2008 Oct 20 (Epub ahead of print).
13. Ruetten H, Thiemermann C: Endothelin-1 stimulates the biosynthesis of tumour necrosis factor in macrophages: ET-receptors, signal transduction and inhibition by dexamethasone. J Physiol Pharmacol 1997, 48:675-688.
14. Suvorava T, Kojda G: Reactive oxygen species as cardiovascular mediators: lessons from endothelial-specific protein overexpression mouse models. Biochim Biophys Acta 2009, 1787:802-810.
15. Madesh M, Hawkins BJ, Milovanova T, et al.: Selective role for superoxide in InsP3 receptor-mediated mitochondrial dysfunction and endothelial apoptosis. J Cell Biol 2005, 170:1079-1090.
16. Papaharalambus CA, Griendling KK: Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury. Trends Cardiovasc Med 2007, 17:48-54.
17. de Winther MP, Kanters E, Kraal G, Hofker MH: Nuclear factor kappaB signaling in atherogenesis. Arterioscler Thromb Vasc Biol 2005, 25:904-914.
18. Martinez-Hervas S, Real JT, Ivorra C, et al.: Increased plasma xanthine oxidase activity is related to nuclear factor kappa beta activation and inflammatory markers in familial combined hyperlipidemia. Nutr Metab Cardiovasc Dis 2009 Sep 16 (Epub ahead of print).
19. Spiekermann S, Landmesser U, Dikalov S, et al.: Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 2003, 107:1383-1389.
20. Baldus S, Koster R, Chumley P, et al.: Oxypurinol improves coronary and peripheral endothelial function in patients with coronary artery disease. Free Radic Biol Med 2005, 39:1184-1190.
21. Berry CE, Hare JM: Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 2004, 555:589-606.
22. Kang DH, Park SK, Lee IK, Johnson RJ: Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005, 16:3553-3562.
23. Saavedra WF, Paolocci N, St John ME, et al.: Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res 2002, 90:297-304.
24. Zweier JL, Broderick R, Kuppusamy P, et al.: Determination of the mechanism of free radical generation in human aortic endothelial cells exposed to anoxia and reoxygenation. J Biol Chem 1994, 269:24156-24162.
25. Terada LS, Rubinstein JD, Lesnefsky EJ, et al.: Existence and participation of xanthine oxidase in reperfusion injury of ischemic rabbit myocardium. Am J Physiol 1991, 260:H805-H810.
26. Nielsen VG, Weinbroum A, Tan S, et al.: Xanthine oxidoreductase release after descending thoracic aorta occlusion and reperfusion in rabbits. J Thorac Cardiovasc Surg 1994, 107:1222-1227.
27. Guan W, Osanai T, Kamada T, et al.: Effect of allopurinol pretreatment on free radical generation after primary coronary angioplasty for acute myocardial infarction. J Cardiovasc Pharmacol 2003, 41:699-705.
28. Ames BN, Cathcart R, Schwiers E, Hochstein P: Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981, 78:6858-6862.
29. Gagliardi AC, Miname MH, Santos RD: Uric acid: a marker of increased cardiovascular risk. Atherosclerosis 2009, 202:11-17.
30. Johnson RJ, Kang DH, Feig D, et al.: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003, 41:1183-1190.
31. Wheeler JG, Juzwishin KD, Eiriksdottir G, et al.: Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med 2005, 2:e76.
32. Keenan RT, Pillinger MH: Hyperuricemia, gout, and cardiovascular disease - an important "muddle." Bull NYU Hosp Jt Dis 2009, 67:285-290.
33. Abbott RD, Brand FN, Kannel WB, Castelli WP: Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol 1988, 41:237-242.
34. Brand FN, McGee DL, Kannel WB, et al.: Hyperuricemia as a risk factor of coronary heart disease: the Framingham Study. Am J Epidemiol 1985, 121:11-18.
35. Niskanen LK, Laaksonen DE, Nyyssonen K, et al.: Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004, 164:1546-1551.
36. Hoieggen A, Alderman MH, Kjeldsen SE, et al.: The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004, 65:1041-1049.
37. Strazzullo P, Puig JG: Uric acid and oxidative stress: relative impact on cardiovascular risk? Nutr Metab Cardiovasc Dis 2007, 17:409-414.
38. Ioachimescu AG, Brennan DM, Hoar BM, et al.: Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum 2008, 58:623-630.
39. Wannamethee SG, Shaper AG, Whincup PH: Serum urate and the risk of major coronary heart disease events. Heart 1997, 78:147-153.
40. Okura T, Higaki J, Kurata M, et al.: Elevated serum uric acid is an independent predictor for cardiovascular events in patients with severe coronary artery stenosis: subanalysis of the Japanese Coronary Artery Disease (JCAD) Study. Circ J 2009, 73:885-891.
41. Madsen TE, Muhlestein JB, Carlquist JF, et al.: Serum uric acid independently predicts mortality in patients with significant, angiographically defined coronary disease. Am J Nephrol 2005, 25:45-49.
42. Chen JH, Chuang SY, Chen HJ, et al.: Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum 2009, 61:225-232.
43. Kuo CF, See LC, Luo SF, et al.: Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford) 2010, 49:141-146. This is one of the most recent and largest population-based studies evaluating the association between hyperuricemia and CVD.
44. Stamler J, Wentworth D, Neaton JD: Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986, 256:2823-2828.
45. Krishnan E, Baker JF, Furst DE, Schumacher HR: Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006, 54:2688-2696.
46. Krishnan E, Svendsen K, Neaton JD, et al.: Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008, 168:1104-1110.
47. Sica DA, Weber M: The Losartan Intervention for Endpoint Reduction (LIFE) trial - have angiotensin-receptor blockers come of age? J Clin Hypertens (Greenwich) 2002, 4:301-305.
48. Tsioufis C, Chatzis D, Vezali E, et al.: The controversial role of serum uric acid in essential hypertension: relationships with indices of target organ damage. J Hum Hypertens 2005, 19:211-217.
49. Doehner W, Schoene N, Rauchhaus M, et al.: Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002, 105:2619-2624.
50. Hare JM, Mangal B, Brown J, et al.: Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol 2008, 51:2301-2309.
51. Kim SY, Guevara JP, Kim KM, et al.: Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009, 61:885-892.
52. Lehto S, Niskanen L, Ronnemaa T, Laakso M: Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 1998, 29:635-639.
53. Weir CJ, Muir SW, Walters MR, Lees KR: Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003, 34:1951-1956.
54. Wong KY, MacWalter RS, Fraser HW, et al.: Urate predicts subsequent cardiac death in stroke survivors. Eur Heart J 2002, 23:788-793.